Amphastar Q2 Revenue Hits $183.9M, BAQSIMI® Milestone Triggers $100M Lilly Payment
AMPH sits 22% above its 52-week low of $16.645.
Summary
Amphastar reported Q2 2026 net revenues of $183.9M, up 5% YoY, with GAAP EPS of $0.67 and adjusted non-GAAP EPS of $0.91. The BAQSIMI® franchise hit its first annual net sales milestone of $175.0M, triggering a $100.0M payment to Eli Lilly due in Q3 2026 — a significant cash outflow but also a sign of commercial traction. Gross margins expanded and the company launched ipratropium bromide, adding $8.4M in sales. This follows a challenging Q1 where net income fell 75% and an FDA warning letter was issued to a subsidiary. The results show a rebound in profitability and pipeline execution, though the Lilly payment will pressure near-term cash. The conference call at 2:00 p.m. PT may provide color on the warning letter remediation and BAQSIMI® growth trajectory.
At the time of this announcement, AMPH was trading at $20.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $873.5M. The 52-week trading range was $16.65 to $31.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.